Efficacy and safety of monoclonal antibody therapy for chronic rhinosinusitis with nasal polyposis

Enache, Raluca; Bejenariu, Andreea; Sarafoleanu, Codrut

doi:10.2478/rjr-2022-0024

Abstract

Chronic rhinosinusitis (CRS) is one of the most common chronic inflammatory syndromes reported in the general population, with high prevalence reported. It is classified in two distinct entities depending on the endotype dominance, either type 2 or non-type 2, – chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic rhinosinusitis without nasal polyps. CRSwNP is described as a type 2 inflammatory disease, with the implication of T-helper 2 inflammation mechanisms with a secondary increase in the concentration of eosinophils and total Immunoglobulin E. CRSwNP is characterized by a high recurrence rate even after endoscopic sinus surgery. Considering the challenges associated with the treatment of CRSwNP, new medical therapies, such as monoclonal antibodies, have been developed over the years.

Biologics with anti-IL-5, anti-IgE, anti-IL-4 receptor alpha (IL-4-Rα) action have been developed and tested for the treatment of asthma, eosinophilic dermatitis, and secondarily evaluated and approved for the treatment of chronic rhinosinusitis with nasal polyps.

In this review, we make a synthesis of the monoclonal antibodies available and their efficacy and safety in the treatment of nasal polyposis.

References

1. Hastan D, Fokkens WJ, Bachert C, Newson RB, Bislimovska J, Bockelbrink A, et al. Chronic rhinosinusitis in Europe – an underestimated disease. A GA-2LEN study. Allergy. 2011;66:1216-23. DOI: 10.1111/j.1398-9995.2011.02646.x.
Open DOI Search in Google Scholar Back to article
2. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1-464. DOI: 10.4193/Rhin20.600.
Open DOI Search in Google Scholar Back to article
3. Schiller JS, Lucas JW, Peregoy JA. Summary health statistics for u.s. Adults: national health interview survey, 2011. Vital Health Stat 10. 2012;(256):1-218.
Search in Google Scholar Back to article
4. Him JH, Cho C, Lee EJ, Suh YS, Choi BI, Kim KS. Prevalence and risk factors of chronic rhinosinusitis in South Korea according to diagnostic criteria. Rhinology. 2016;54(4):239-35. DOI: 10.4193/Rhino15.157.
Open DOI Search in Google Scholar Back to article
5. Shi JB, Fu QL, Zhang H, Cheng L, Wang YJ, Zhu DD, et al. Allergy. 2015;70(5):533-9. DOI: 10.1111/all.12577.
Open DOI Search in Google Scholar Back to article
6. Kim C, Han J, Wu T, Bachert C, Fokkens W, Hellings P, et al. Role of biologics in chronic rhinosinusitis with nasal polyposis: state of the art review. Otolaryngol Head Neck Surg. 2021;164(1):57-66. DOI: 10.1177/0194599820939964.
Open DOI Search in Google Scholar Back to article
7. Patel GB, Peters AT. The role of biologics in chronic rhinosinusitis with nasal polyps. Ear Nose Throat J. 2021;100(1):44-7. DOI: 10.1177/0145561320964653.
Open DOI Search in Google Scholar Back to article
8. Ren L, Zhang N, Zhang L, Bachert C. Biologics for the treatment of chronic rhinosinusitis with nasal polyps – state of art. World Allergy Organ J. 2019;12(8):1000050. DOI: 10.1016/j.waojou.2019.100050.
Open DOI Search in Google Scholar Back to article
9. Lange B, Holst R, Thilsing T, Baelum J, Kjeldsen A. Quality of life and associated factors in persons with chronic rhinosinusitis in the general population: a prospective questionnaire and clinical cross-sectional study. Clin Otolaryngol. 2013;38(6):474-80. DOI: 10.1111/coa.12189.
Open DOI Search in Google Scholar Back to article
10. Benjamin MR, Stevens WW, Li N, Bose S, Grammar L, Kern RC, et al. Clinical characteristics of patients with chronic rhinosinusitis without nasal polyps in an academic setting. J Allergy Clin Immunol Pract. 2019;7(3):1010-16. DOI: 10.1016/j.jaip.2018.10.014.
Open DOI Search in Google Scholar Back to article
11. Tsetsos N, Goudakos JK, Daskalakis D, Konstantinidis I, Markou K. Monocloncal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review. Rhinology. 2018:56:11-21. DOI: 10.4193/Rhino17.156.
Open DOI Search in Google Scholar Back to article
12. Bhattacharyya N, Orlandi RR, Grebner J, Martinson M. Cost burden of chronic rhinosinusitis: a claims-based study. Otolaryngol Head Neck Surg. 2011;144(3):440-5. DOI: 10.1177/0194599810391852.
Open DOI Search in Google Scholar Back to article
13. Loftus CA, Soler ZM, Koochakzadeh S, Desiato VM, Yoo F, Nguyen SA, et al. Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta-analysis of risk factors. Int Forum Allergy Rhinol. 2020;10(2):199-207. DOI: 10.1002/alr.22487.
Open DOI Search in Google Scholar Back to article
14. DeConde AS, Mace JC, Levy JM, Rudmik L, Alt JA, Smith T. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017;127(3):550-5. DOI: 10.1002/lary.26391.
Open DOI Search in Google Scholar Back to article
15. Caminati M, Le Pham D, Bagnasco D, Canonica GW. Type 2 immunity in asthma. World Allergy Organ J. 2018;11(1):13. DOI: 10.1186/s40413-018-0192-5.
Open DOI Search in Google Scholar Back to article
16. Hulse KE, Stevens WW, Tan BK, Schleimer RP. Pathogenesis of nasal polyposis. Clin Exp Allergy. 2015;45(2):328-46. DOI: 10.1111/cea.12473.
Open DOI Search in Google Scholar Back to article
17. Bachert C, Zhang N, Hellings PW, Bousquet J. Endotype-driven care pathways in patients with chronic rhinosinusitis. J allergy Clin Immunol. 2018;141:1543-51.
Search in Google Scholar Back to article
18. Schwarts JS, Tajudeen BA, Cohen NA. Medical management of chronic rhino-sinusitis – a review of traditional and novel medical therapies. Expert Opin Investig Drug. 2017;26:1123-30.
Search in Google Scholar Back to article
19. Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, et al. Humanization of an antibody directed against IgE. J Immunol. 1993;151-2623-32.
Search in Google Scholar Back to article
20. MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997;158:1438-45.
Search in Google Scholar Back to article
21. Genentech Announces FDA Approval of Xolair (omalizumab) for Adults with Nasal Polyps [News Release] December 1, 2020; San Francisco, CA. Accessed December 1, 2020. https://www.gene.com/media/press-releases/14887/2020-12-01/genentech-announces-fda-approval-of-xola.
Search in Google Scholar Back to article
22. European Medicines Agency. Xolair. Omalizumab. [Internet]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/xolair. Accessed July 21, 2022.
Search in Google Scholar Back to article
23. Van Zele T, Holappels G, Gevaert P, Bachert C. Differences in initial immuno-profiles between recurrent and nonrecurrent chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2014;28:192-8.
Search in Google Scholar Back to article
24. Gevaert P, Bachert C, Holtappels G, Novo CP, Van der Heyden J, Fransen L, et al. Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis. Allergy. 2003;58:371-9.
Search in Google Scholar Back to article
25. GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps. [Internet]. GlaxoSmithKline; July 29, 2021. Available from: https://www.gsk.com/en-gb/media/press-releases/gsk-announces-fda-approval-for-nucala-mepolizumab-for-use-in-adults-with-chronic-rhinosinusitis-with-nasal-polyps/. Accessed 21 July 2022.
Search in Google Scholar Back to article
26. European Medicines Agency. Nucala. Mepolizumab. [Internet]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/nucala. Accessed 24 July 2022.
Search in Google Scholar Back to article
27. Steinke JW, Crouse CD, Bradley D, Hise K, Lynch K, Kountakis SE, et al. Characterization of interleukin-4-stimulated nasal polyp fibroblasts. Am J Respir Cell Mol Biol. 2004;30(2):212-9. DOI: 10.1165/rcmb.2003-0071OC.
Open DOI Search in Google Scholar Back to article
28. Pinto JM, Mehta N, DeTineo M, Wang J, Baroody FM, Naclerio RM. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhino-sinusitis. Rhinology. 2010;48:318-324. DOI: 10.4193/Rhino09.144.
Open DOI Search in Google Scholar Back to article
29. Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110-6. DOI: 10.1016/j.jaci.2012.07.047.
Open DOI Search in Google Scholar Back to article
30. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: A randomized clinical trial. JAMA. 2016;315(5):469-79. DOI: 10.1001/jama.2015.19330.
Open DOI Search in Google Scholar Back to article
31. Jonstam K, Swanson BN, Mannent LP, Cardell LO, Tian N, Wang Y, et al. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhino-sinusitis with nasal polyposis. Allergy. 2019;74:743-52. DOI: 10.1111/all.13685.
Open DOI Search in Google Scholar Back to article
32. Bachert C, Hellings PW, Mullol J, Nacleiro RM, Chao J, Amin N, et al. Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. J Allergy Clin Immunol Pract. 2019;7(7):2447-49.e2.
Search in Google Scholar Back to article
33. Fujieda S, Matsune S, Takeno S, Asako M, Takeuchi M, Fujita H, et al. The effect of dupilumab on intractable chronic rhinosinusitis with nasal polyps in Japan. Laryngoscope. 2021;131:E1770-77.
Search in Google Scholar Back to article
34. Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118(5):1133-41. DOI: 10.1016/j.jaci.2006.05.031.
Open DOI Search in Google Scholar Back to article
35. Bachert C, Sousa AR, Lund AJ, Scadding GK, Gevaert P, Nasser S, et al. reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial. J Allergy Clin Immunol. 2017;140(4):1024-31. DOI: 10.1016/j.jaci.2017.05.044.
Open DOI Search in Google Scholar Back to article
36. Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F, et al. Mepolizumab, a humanized anti-IL-5 mAB, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989-65. DOI: 10.1016/j.jaci.2011.07.056.
Open DOI Search in Google Scholar Back to article
37. Controlled clinical study of dupilumab in patients with nasal polyps (SINUS-52). ClinicalTrials.gov Identifier: NCT02898454. [Internet]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02898454.
Search in Google Scholar Back to article
38. A controlled clinical study of dupilumab in patients with bilateral nasal polyps (SINUS-24). ClinicalTrials.gov Identifier: NCT02912468. [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT02912468.
Search in Google Scholar Back to article
39. A clinical trial of omalizumab in participants with chronic rhinosinusitis with nasal polyps (POLYP 1). ClinicalTrials.gov Identifier: NCT03280550. [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03280550.
Search in Google Scholar Back to article
40. A clinical trial of omalizumab in pariticipants with chronic rhinosinusitis with nasal polyps (POLYP 2). ClinicalTrials.gov Identifier: NCT03280537. [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03280537.
Search in Google Scholar Back to article
41. Effect of mepolizumab in severe bilateral nasal polyps. ClinicalTrials.gov Identifier: NCT03085797. [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03085797.
Search in Google Scholar Back to article
42. Efficacy and safety study of benralizumab for patients with severe nasal polyposis (OSTRO). ClinicalTrial.gov Identifier: NCT03401229. [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03401229.
Search in Google Scholar Back to article
43. Nasal polyps: Inflammatory & molecular phenotyping of responders to benralizumab (NAPPREB). ClinicalTrials.gov Identifier: NCT04185012. [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT04185012.
Search in Google Scholar Back to article
44. Lund VJ, Mackay IS. Staging in rhinosinusitis. Rhinology. 1993;31(4):183-4.
Search in Google Scholar Back to article
45. Chuang CC, Guillemin I, Bachert C, Lee SE, Hellings PW, Fokkens WJ, et al. Dupilumab in CRSwNP: responder analysis using clinically meaningful efficacy outcome thresholds. Laryngoscope. 2022;132:259-64. DOI: 10.1002/lary.29911.
Open DOI Search in Google Scholar Back to article
46. Bachert C, Zinreich SJ, Hellings PW, Mullol J, Hamilos DL, Gavaert P, et al. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP. Rhinology. 2020;58(1):10-7. DOI: 10.4193/Rhin18.282.
Open DOI Search in Google Scholar Back to article
47. Bachert C, Han JK, Desrosiers MY, Gevaert P, Heffler E, Hopkins C, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial. J Allergy Clin Immunol. 2022;149:1309-17.
Search in Google Scholar Back to article
48. Chong LY, Piromchai P, Sharp S, Snidvongs K, Webster KE, Philpott C, et al. Biologics for chronic rhinosinusitis. Cochrane Database of Systematic Reviews. 2021;3.
Search in Google Scholar Back to article
49. Doty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. Laryngoscope. 1984;94(2 Pt 1):176-8. DOI: 10.1288/00005537-198402000-00004.
Open DOI Search in Google Scholar Back to article
50. Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(5):1449-56.e4. DOI: 10.1016/j.jaci.2015.12.1324.
Open DOI Search in Google Scholar Back to article
51. Camelo A, Rosignoli G, Ohne Y, Stewart RA, Overed-Sayer C, Sleeman MA, et al. IL-33, IL-25, and TSLP induce a distinct phenotypic and activation profile in human type 2 innate lymphoid cells. Blood Adv. 2017;1(10):577-89. DOI: 10.1182/bloodadvances.2016002352.
Open DOI Search in Google Scholar Back to article
52. Fokkens WJ, Lund V, Bachert C, Mullol J, Bjermer L, Bousquet J, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(2):2312-9. DOI: 10.1111/all.13875.
Open DOI Search in Google Scholar Back to article
53. Scangas GA, Wu AW, Ting JY, Metson R, Walgama E, Shrime MG, et al. Cost utility analysis of dupilumab versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps. Laryngoscope. 2021;131(1):E26-33. DOI: 10.1002/lary.28648.
Open DOI Search in Google Scholar Back to article
54. Smith KA, Orlandi RR, Rudmik L. Cost of adult rhinosinusitis: A systematic review. Laryngoscope. 2015;125(7):1547-56. DOI: 10.1002/lary.25180.
Open DOI Search in Google Scholar Back to article
55. Andreson WC 3rd, Szefler SJ. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or nor to biologic? Ann Allergy Asthma Immunol. 2019;122(4):367-72. DOI: 10.1016/j.anai.2019.01.018.
Open DOI Search in Google Scholar Back to article
56. Lam K, Kern RC, Luong A. Is there a future for biologics in the management of chronic rhinosinusitis? Int Forum Allergy Rhinol. 2016;6(9):935-42. DOI: 10.1002/alr.21780.
Open DOI Search in Google Scholar Back to article
57. Wang WW, Lu DM, Zheng M, Zhang JG, Zhang B. TSLP regulates eotaxin-1 production by nasal epithelial cells from patients with eosinophilic CRSwNP. Rhinology. 2018;56(4):370-7. DOI: 10.4193/Rhin17.045.
Open DOI Search in Google Scholar Back to article
58. Kim DK, Jin HR, Eun KM, Mo JH, Cho SH, Oh S, et al. The role of interleukin-33 in chronic rhinosinusitis. Thorax. 2017;72(7):635-45.
Search in Google Scholar Back to article
59. Luo X, Li C, Wang Y, Yang G, Xu Y, Li G, et al. Interleukin-33 promotes Th2/Th17 response in eosinophilic and non-eosinophilic nasal polyps. ORL J Otorhinolaryngol Relat Spec. 2020;82(1):34-9.
Search in Google Scholar Back to article
60. Nagarkar DR, Poposki JA, Tan BK, Comeau MR, Peters AT, Hulse KE, et al. Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2013;132(3):593-600. DOI: 10.1016/j.jaci.2013.04.005.
Open DOI Search in Google Scholar Back to article

Efficacy and safety of monoclonal antibody therapy for chronic rhinosinusitis with nasal polyposis

Abstract

Paradigm

My account